Immunocore to present at upcoming investor conferences
2024年3月1日 - 9:00PM
Immunocore to present at upcoming
investor conferences
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md., US, 01 March 2024) Immunocore Holdings plc
(Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage
biotechnology company pioneering and delivering transformative
immunomodulating medicines to radically improve outcomes for
patients with cancer, infectious diseases and autoimmune diseases,
today announced that management will participate in the following
investor conferences in March:
- TD Cowen
44th Annual Healthcare
Conference
Fireside Chat: Tuesday, March 5, 2024, at 11:10
a.m. EST
- Leerink Partners Global
Biopharma Conference
1x1 and small group meetings: Tuesday, March 12,
2024
- Jefferies Biotech on the
Bay
1x1 and small group meetings: Wednesday, March
13, 2024
- Barclays 26th Annual
Global Healthcare Conference Fireside Chat: Thursday,
March 14, 2024, at 9:30 a.m. EST
Where relevant, the presentations will be
webcast live and can be accessed by visiting ‘Events’, under ‘News
& Events’, via the ‘Investors’ section of Immunocore’s website
at www.immunocore.com. Following the event, a replay of the
presentations will be made available for a limited time.
About
Immunocore Immunocore is a commercial-stage
biotechnology company pioneering the development of a novel class
of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing
monoclonal TCRs Against X disease – designed to treat a broad range
of diseases, including cancer, autoimmune, and infectious disease.
Leveraging its proprietary, flexible, off-the-shelf ImmTAX
platform, Immunocore is developing a deep pipeline in multiple
therapeutic areas, including five clinical stage programs in
oncology and infectious disease, advanced pre-clinical programs in
autoimmune disease and multiple earlier pre-clinical programs. The
Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been
approved for the treatment of HLA-A*02:01-positive adult patients
with unresectable or metastatic uveal melanoma in the United
States, European Union, Canada, Australia, and the United
Kingdom.
CONTACT: Immunocore Sébastien
Desprez, Head of Communications T: +44 (0) 7458030732 E:
sebastien.desprez@immunocore.com Follow
on Twitter: @Immunocore
Investor Relations Clayton Robertson,
Head of Investor Relations T: +1 215-384-4781 E:
ir@immunocore.com
Immunocore (NASDAQ:IMCR)
過去 株価チャート
から 1 2025 まで 2 2025
Immunocore (NASDAQ:IMCR)
過去 株価チャート
から 2 2024 まで 2 2025